ClinicalTrials.Veeva

Menu

Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections

H

Hvidovre University Hospital

Status and phase

Unknown
Phase 3

Conditions

Clostridium Difficile

Treatments

Drug: Vancomycin
Drug: Fecal microbiota transplantation
Drug: Rectal bacteriotherapy

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of the study is to investigate if treatment with fecal microbiota transplantation or rectal bacteriotherapy is superior to standard vancomycin in patients with recurrent Clostridium Difficile infections.

Full description

Clostridium difficile infection (CDI) is the most common nosocomial infection in the western world. CDI is associated with high morbidity and mortality and is a great burden for the health care system leading Center of Disease Control and Prevention (CDC) to identify it as one of three most important/urgent threats to public health.

Despite antimicrobial treatment of CDI, 20% of the patients have recurrence of CDI. Due to a dysbiosis in the gut microbiota the antimicrobial treatment seems to be less effective.

Fecal microbiota transplantation (FMT) is an alternative treatment for recurrent CDI. Studies have shown a cure rate up to 90% in patients with recurrent CDI. One alternative to FMT is rectal bacteriotherapy (RBT) which is a standardized bacterial culture made in the laboratory consisting of 12 different bacteria. RBT has never been investigated in a clinical trial.

The project is a randomized controlled trial including 450 patients with recurrent CDI will be, after accepting participation, allocated to receive vancomycin alone or vancomycin followed by either FMT or RBT. The patients will be followed up for 180 days. Cure is defined as resolution of CDI symptoms 90 days after treatment.

Enrollment

450 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years
  • Verified recurrent CDI with symptoms of CDI and microbiological verification (PCR).
  • Previously treated for CDI with at least 10 days of vancomycin or metronidazole.
  • Be able to read and understand Danish.

Exclusion criteria

  • Life expectancy < 3 months.
  • Allergy toward vancomycin
  • Other infection in the GI tract with clinical symptoms similar to CDI.
  • Other illness in the GI tract with clinical symptoms similar to CDI.
  • Use of antibiotics for more than 14 days treating other infections
  • Planning pregnancy, pregnancy or breast feeding.
  • Severe immune suppression which makes FMT/RBT relatively contraindicated

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

450 participants in 3 patient groups

Vancomycin
Active Comparator group
Description:
Oral vancomycin according to number of recurrences (Danish guidelines): First recurrence: Capsule vancomycin 125 mg x 4 p.o. times daily for 14 days ≥2 recurrences: * capsule vancomycin 125 mg x 4 times daily p.o. for 14 days followed by * capsule vancomycin 125 mg x 2 times daily p.o. for 7 days followed by * capsule vancomycin 125 mg x 1 times daily p.o. for 7 days followed by * capsule vancomycin 125 mg x 1 p.o. every second day for 7 days followed by * capsule vancomycin 125 mg x 1 p.o. every third day for 14 days
Treatment:
Drug: Vancomycin
Vancomycin + fecal microbiota transplantation
Experimental group
Description:
Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
Treatment:
Drug: Vancomycin
Drug: Fecal microbiota transplantation
Vancomycin + rectal bacteriotherapy
Experimental group
Description:
Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Rectal bacteriotherapy with 200 ml suspension of a fixed mixture of bacterial strains administrated with a rectal catheter.
Treatment:
Drug: Vancomycin
Drug: Rectal bacteriotherapy

Trial contacts and locations

2

Loading...

Central trial contact

Andreas M Petersen, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems